REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the...

Related Keywords

United States ,Brazil ,Dana Cormack ,Chris Brinzey ,Steve Pakola ,Technology Platform ,Technology Platform Licensees ,Drug Administration ,Nasdaq ,Exchange Commission ,Corporate Communications ,Securities Exchange ,Manufacturing Innovation Center ,Chief Medical Officer ,Mucopolysaccharidosis Type ,Chief Executive Officer ,Fast Track ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Regenxbio Inc ,